Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 11, 2023 07:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

CONSHOHOCKEN, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
August 08, 2023 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug AdministrationNASH disease education and market development activities expand to support potential first-to-market launch in...
July 17, 2023 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

CONSHOHOCKEN, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
June 30, 2023 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Madrigal expects to complete full submission of the New Drug Application in July 2023 CONSHOHOCKEN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a...
June 22, 2023 03:30 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™

First scientific presentation of detailed MAESTRO-NASH results confirms achievement of primary endpoints across multiple patient subgroupsNoninvasive imaging and biomarker data support findings on...
June 06, 2023 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Supports International NASH Day on June 8

CONSHOHOCKEN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
June 01, 2023 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

CONSHOHOCKEN, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
May 11, 2023 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

CONSHOHOCKEN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
May 09, 2023 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

Resmetirom new drug application (NDA) filing on track for Q2 2023Resmetirom has received Breakthrough Therapy designation from FDA Multiple resmetirom abstracts accepted for presentation at EASL,...
April 18, 2023 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial

CONSHOHOCKEN, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right